-+ 0.00%
-+ 0.00%
-+ 0.00%

Nanobiotix Nanoprimer Pre-Treatment Demonstrates Reduced Hepatic Toxicity And Improved Systemic Bioavailability For LNP-DNA Cancer Immunotherapy In Preclinical Study

Benzinga·04/20/2026 07:49:45
Listen to the news
  • Preclinical evaluation in mice assessed the potential of the Nanobiotix Nanoprimer to overcome common barriers faced by lipid nanoparticle("LNP")-delivered therapies related to rapid liver clearance
  • Pre-treatment with Nanoprimer followed by administration of LNP-delivered recombinant DNA ("LNP-DNA") designed for anti-tumor immunotherapy showed increased systemic bioavailability, reduced hepatic toxicity, and reduced cGAS-STING related inflammation compared to LNP-DNA administered without the Nanoprimer